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E-mail: dkohn@mednet.ucla.eduHematopoietic stem cell gene therapy is a promising approach
for treating disorders of the hematopoietic system. Identifying
combinations of cis-regulatory elements that do not impede
packaging or transduction efficiency when included in lentivi-
ral vectors has proven challenging. In this study, we deploy LV-
MPRA (lentiviral vector-based, massively parallel reporter
assay), an approach that simultaneously analyzes thousands
of synthetic DNA fragments in parallel to identify sequence-
intrinsic and lineage-specific enhancer function at near-base-
pair resolution. We demonstrate the power of LV-MPRA in
elucidating the boundaries of previously unknown intrinsic
enhancer sequences of the human b-globin locus control
region. Our approach facilitated the rapid assembly of novel
therapeutic bAS3-globin lentiviral vectors harboring strong
lineage-specific recombinant control elements capable of cor-
recting a mouse model of sickle cell disease. LV-MPRA can
be used to map any genomic locus for enhancer activity and
facilitates the rapid development of therapeutic vectors for
treating disorders of the hematopoietic system or other specific
tissues and cell types.
INTRODUCTION
Hematopoietic stem cell gene therapy is a promising approach for
treating manymonogenic disorders of the hematopoietic system, hav-
ing demonstrated remarkable success in a number of phase I/II clin-
ical trials.1–12 Therapeutic lentiviral vectors typically contain human
cis-regulatory elements that provide high-level, lineage-specific
expression of a therapeutic transgene. Identification of appropriate
cis-regulatory elements that do not impede packaging or transduction
efficiency when included in lentiviral vectors (LVs) has been a major
challenge in developing novel gene therapy vectors.13–19
The elements used in LVs to confer tightly regulated expression of
therapeutic transgenes are often identified by contrasting mouseMolecular Therapy: Methods &
This is an open access article under the CC BY-NC-knockout studies20–28 to histone marking and accessibility data29 to
determine putative boundaries of cis-regulatory elements. Although
aforementioned technologies have enabled the identification of
candidate cis-regulatory elements for incorporation into LVs,
these technologies fail to provide insight on the exact base pair (bp)
boundaries of bona fide “sequence-intrinsic” enhancers (i.e., the
actual sequences providing enhancer activity). Moreover, when
chromatin marking and accessibility data are used to identify putative
regulatory elements, detection of appropriate cell type-specific
control elements can be confounded by extrinsic factors such as
chromatin state, cell cycle, cell state, cell type, antibody sensitivity/
specificity, and protein evanescence. The proposed control sequences
must still be functionally tested for their ability to enhance transgene
expression, which is a low-throughput process when attempting to
identify the best combination of elements to include in LVs.
To overcome the limitations of current methods used to detect cell-
specific enhancer elements for use in therapeutic vector design, we
developed a massively parallel reporter assay (MPRA) to pinpoint
and identify boundaries of human genomic sequences capable
of driving cell type-specific LV reporter gene expression. Similar as-
says have been used to map promoter activity30 and measure
enhancer activity,31–34 and they have provided novel insights into
the complex relationships between nucleotide composition and
regulatory activity.35–40Clinical Development Vol. 17 June 2020 ª 2020 The Author(s). 999
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as our target, a region known to contain potent lineage-specific en-
hancers that drive the temporal and developmentally specific expres-
sion of the b-globin gene locus.41 Previous studies examining the influ-
ence of each LCR DNase hypersensitive site on transgene expression
incorporated minimal hypersensitive sites (HS) sequences (typically
200–400 bp [referred to as HS core regions]) with flanking sequences
into LVs to achieve position-independent expression.18,42 Full
enhancer activity of any given HS sequence was only realized once
larger sequences containing both core and associated flanking se-
quences were incorporated into LVs, work that was largely enabled
by the significant contributions of the Engel, Grosveld, and Stama-
toyannopoulos laboratories, among others.20,43,44 While DNA se-
quences within the cores are very well conserved, as are blocks of se-
quences found outside the core regions,45 an exhaustive survey
examining the functional significance of LCR core and flanking se-
quences had yet to be implemented at high-resolution before our effort.
In this study, we show that LV-based MPRA (LV-MPRA) was able to
map the functional cis-regulatory elements possessing enhancer activ-
ity at near-base-pair resolution. The map generated by LV-MPRA
guided the construction of an array of novel recombinant regulatory
elements that conferred a range of transgene expression in human
erythrocytes that correlated with the length of concatenated enhancer
combinations, allowing us to generate, in mere weeks, a vector con-
taining enhancers of novel composition that rivaled the performance
of those in a clinical vector that have undergone nearly two decades of
refinement.13,46
Finally, we demonstrated that novel therapeutic b-globin LV constructs
generated using LV-MPRA data, selected for optimal size and expres-
sion, faithfully corrected the disease phenotype in a mouse model of
sickle cell disease (SCD), demonstrating the promise of this approach
in accelerating development of clinically relevant and novel vectors.
RESULTS
LV-MPRA Identifies Sequence-Intrinsic Enhancers of the
b-Globin Locus Control Region
Tomap enhancers throughout the LCR, we designed a reporter vector
that contained only the minimal human b-globin promoter as theFigure 1. Overview of LV-MPRA Library Design and Experimental Workflow
(A) Overlapping 103-bp b-globin locus control region (LCR) sequences were generated
preceding sequence. Three unique barcodes (BCs) were assigned to each sequence, an
new BCs. A total of ~4.2 103 unique oligonucleotides were needed to achieve 1 cove
unique 13-bp barcodes, tripling the diversity of sequences to ~1.2 104. Antisense vers
sequences to ~2.5  104. (B) A schematic of a single 170-mer is provided. (1) The 170
plasmid backbone and required for downstream cloning. The 103-bp LCR (query) sequ
downstream cloning. (2) A pool of 170 mer generated by DNA microarray were convert
dsDNA fragments were joined to lentiviral vector plasmid backbones by Gibson assemb
digested with restriction enzymes and an expression cassette (b-globin promoter/bAS3-
placement of the query sequence upstream of the promoter and placement of the BC
strength by BC abundance. (C) The complete LV reporter library was packaged into le
HUDEP-2. The abundance of cDNA BCs were quantified and normalized to the abu
intrinsic enhancers.
Moleculamajor cis-regulatory element driving expression of the bAS3-P2A-
mCitrine (mCit) transgene.47,48 We then incorporated a 103-bp
sequence derived from the LCR’s HS2 core region into the multiple
cloning site of LV-reporter (Figure S1A), as HS2 has been shown to
possess robust erythroid-specific enhancer activity throughout all
stages of human development.28 The 103-bp HS2 enhancer sequence
provided increased expression of the reporter gene in human umbil-
ical cord blood-derived erythroid progenitor clone 2 (HUDEP-2)49
cells when compared to control (Figures S1B and S1C). This finding
suggested that100-bp regions of the LCR could enhance expression
from the minimal human b-globin promoter. Thus, LV-reporter
became the basis of what was used to analyze thousands of overlap-
ping 100-bp LCR sequences in parallel for enhancer activity.
The LV-MPRA experimental strategy consisted of three steps: (1) in
silico bar-coded LCR segment library design and construction, (2) li-
brary packaging, cell line transduction, and culture, and (3) barcode
acquisition, sequencing, and data analysis.
First, a library of overlapping 103-bp LCR “query” sequences was de-
signed by in silico tiling. Overlapping sequences were generated with
the start of subsequent sequences beginning 4 bp after the start of a
preceding sequence. The collection of sequences was duplicated three
times by associating three unique 13-bp barcodes with each sequence.
The resultant sequence collection was duplicated a second time by re-
placing all sequences with reverse complement sequences and assign-
ing new barcodes. In total, a collection of 25,000 unique LCR/bar-
code sequence combinations were generated with a maximum of
150 coverage per bp (Figure 1A).
The library of LCR sequence and barcode pairs were synthesized via
DNA microarray as 170-bp oligonucleotides. A schematic of a single
170-mer is shown in Figure 1B. The length of any given query
sequence was fixed at 103 bp, as the DNA microarray was limited
to synthesizing 170 mer, and 67 bp of sequence was needed for
backend library construction/sequencing. A cloning strategy was
deployed that allowed for placement, en masse, of query sequences
upstream of the minimal b-globin promoter, as well as placement
of corresponding barcodes between the bAS3-P2A-mCit sequence
and 30 UTR of the transcriptional cassette. Thus, the strength of awith 4-bp tiling. The start of subsequent sequences began 4 bp after the start of a
d the entire sequence collection was duplicated in reverse orientation and assigned
rage of the larger 16-kb LCR sequence. Each “query” sequence was assigned three
ions of the query sequences were also included, doubling the total number of unique
-mer is flanked by 20-bp arms at each end, with each possessing homology to the
ence and 13-bp barcode are separated by BmtI and SalI restriction sites to facilitate
ed into dsDNA by primer extension and then PCR amplified. (3) The pool of 170-bp
ly to ensure 1:1 fusions of 170-bp dsDNA fragments to plasmid. The library was then
globin gene/p2A/mCitrine) introduced by ligation. (4) The complete library provides
upstream of a polyadenylation signal to allow for determination of query sequence
ntiviral particles and virus used to transduce the erythroid progenitor-like cell line,
ndance of plasmid DNA BCs to detect and measure the strength of sequence-
r Therapy: Methods & Clinical Development Vol. 17 June 2020 1001
Molecular Therapy: Methods & Clinical Developmentquery sequence could be quantified by the abundance of barcodes ex-
pressed in mRNA. The transcriptional cassette was kept in reverse
orientation in respect to viral RNA production to retain introns
during viral genome packaging. Completeness of the starting plasmid
library was confirmed by sequencing (Figure S2A).
Second, the plasmid library was packaged into viral particles and
used to transduce the HUDEP-2 cell line at a multiplicity of infection
(MOI) of 4. To verify that packaging and cell line transduction did
not negatively influence library complexity, we quantified barcode
abundance in the starting plasmid pool and in genomic DNA
(gDNA) of transduced HUDEP-2 cells. The correlation between
barcodes in the plasmid pool and gDNA of transduced HUDEP-2
cells was strong (r = 0.854), demonstrating that the diversity of
barcodes in the starting plasmid pool was efficiently transferred to
the integrated proviral barcode pool of transduced HUDEP-2 cells
(Figure S2B; each dot in the dot plot represents the log10 value of
an individual barcode found in the plasmid barcode pool, integrated
proviral barcode pool, or both). Vector copy number (VCN) in the
bulk transduced HUDEP-2 cell population was found to be 9.7 by
digital droplet (DD) PCR.
Lastly, barcodes were obtained frommRNA of transduced HUDEP-2
cells and sequenced after cells were differentiated down the erythroid
lineage for 4 days. The correlation between mRNA and gDNA
barcodes was low (r = 0.304), demonstrating that only a subset of
query sequences possessed enhancer activity (Figure S2C). To
generate a map of enhancer activity across the LCR, barcode reads
were normalized by sequencing depth and enhancer activity calcu-
lated by dividing RNA barcode counts by plasmid DNA barcode
counts. Plasmid barcode counts were chosen as the normalization
factor, as we were only interested in identifying enhancer sequences
that were successfully packaged to enhance expression once viral
genomes were stably integrated into HUDEP-2 cells.
Expression values were generated for each starting position by
averaging normalized counts of three corresponding barcodes per
position. Averaged normalized counts were then plotted to their cor-
responding positions across a map of the LCR. Statistical bootstrap-
ping was then used to determine an “enhancing score” for a given
query sequence by resampling the neighboring 50 values 100,000
times and then replacing that value with the estimated value in an
iterative fashion. The bootstrapping process allowed for reduction
of noise, as clusters of neighboring sequences offered similar levels
of expression activity due to the narrow sequence length assayed.
The resulting map of enhancer activity across the LCR is provided
in Figure 2A. Highlighted regions represent boundaries of LCR
regulatory elements characterized in transgenic mice as erythroid
cell-specific DNase I hypersensitive sites required for high-level,
position-independent expression.20–28 As shown, most peaks within
the LCR that represent sequences with strong intrinsic enhancer
activity fall within the boundaries of classically defined LCR control
elements. The same map is shown in Figure S2D, this time aligned1002 Molecular Therapy: Methods & Clinical Development Vol. 17 Juneto ENCODE track sets denoting regions of open chromatin and
other markings in K562 cells http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&position=chr11:5296481-5313207 (GRCh37/
hg19; University of California Santa Cruz [UCSC] Genome Browser),
markings that when present in specific combinations suggest the
presence of enhancers.50 Furthermore, when components of compos-
ite enhancers were aligned with the endogenous human b-globin
LCR, those components fell well within the boundaries of Lenti/
bAS3-FB’s full-length HS sequences (Figure S3).
To determine whether the presence of specific transcription factor
binding sites (TFBSs) were predictive of intrinsic enhancer strength,
the presence of key putative erythroid-specific TFBSs (GATA1, KLF1,
and TAL1) were identified and aligned to the map of normalized bar-
code counts (Figure 2B). The presence of putative erythroid-specific
TFBSs were seen to align closely with intrinsic enhancer peaks above
the 95th percentile of highest expression. These findings are consis-
tent with previous reports that highlight the role of GATA1, KLF1,
and TAL1 in modulating expression of erythroid-specific genes.51,52
Densities of putativeTFBSswere also found tobepredictive of enhancer
strength. Putative TFBSs were identified along the LCR using FIMO
(Find Individual Motif Occurrences),53 an algorithm that scans a given
DNA region for individual TFBS consensus sequence matches. Fig-
ure 2C provides a density map of FIMOTFBSmatches plotted by loca-
tion across the LCR. Locationswith quantities of putative TFBSs greater
than 40 were seen to align closely with sequence-intrinsic enhancer
peaks that were above the 95th percentile of highest expression.
LV-MPRA-Guided Therapeutic Vector Design and
Characterization
A series of b-globin expression constructs were designed by imposing
thresholds to cluster LCR sequences that were within the 80th, 90th,
95th, 97.5th, or 98.75th percentiles of highest enhancer activity (Fig-
ure 3A) (see Figure S3 for alignment of novel LCR enhancers to the
entire b-globin LCR and to the LCR element contained within the
Lenti/bAS3-FB vector). Concatenated enhancer combinations were
each cloned in sense orientation into the identical b-globin expression
vector backbone and compared head-to-head against Lenti/bAS3-FB,
which was deemed to be the strongest expressing globin vector by way
of its full-length HS2, HS3, and HS4 elements (totaling 3.6 kb in
sequence length).
The LV-MPRA-guided constructs, termed 80, 90, 95, 97.5, and 98.75
(based on the percentile cutoff thresholds used to identify sequences
for concatenation within a given percentile of expression), were
packaged in parallel against Lenti/bAS3-FB using HEK293T cells
and titered head-to-head on HT-29 cells. An inverse correlation
was observed when titer was plotted as a function of enhancer
length, demonstrating that overall enhancer length strongly influ-
enced infectious particle production (Figure 3B).
To measure the infectivity of the different vectors, human CD34+
hematopoietic stem and progenitor cells (HSPCs) were transduced2020
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Figure 2. Sequence-Intrinsic Enhancer Map Spanning
the b-Globin Locus Control Region
(A) A map of enhancer activity across the LCR is provided.
Highlighted regions represent boundaries of LCR-hyper-
sensitive sites (HS1–HS5) as defined in previous literature.
PC, positive control with known enhancer sequence from
HS2. Track sets available through ENCODE denoting re-
gions of open chromatin and other markings are provided
as a reference. (B) A map of important erythroid-specific
transcription factor binding sites. (C) A map of putative
transcription factor binding sites across the LCR. High-
lighted regions represent boundaries of LCR-hypersensitive
sites as defined in previous literature.
www.moleculartherapy.orgat a fixed MOI of 10 (1.0  107 TU/mL; based on titers measured on
HT-29 cells). Transduced CD34+ cells were cultured for 14 days
followed by extraction of gDNA for measurement of VCN. An
inverse relationship was observed between enhancer length and
VCN, which reflects relative infectivity of the different vectors
when used at the same MOI (Figure 3C; Table 1).
Transduction efficiency was then assessed across a range of MOIs
(1, 3.3, 6.6, or 10). Linear regression analysis revealed a positive
correlation between infectivity and vector dose while demon-
strating an inverse correlation between infectivity and enhancer
length (Figure 3D). Indeed, the observation that overall vector
length is the strongest factor influencing both packaging and
transduction efficiency, rather than the presence of discrete se-
quences, is well supported.54–56 However, the role sequence plays
in packaging efficiency cannot be overlooked. For example,
enhancer elements containing cryptic polyadenylation sequences
can prematurely terminate viral genome synthesis, leading to sig-
nificant decreases in titers.Molecular Therapy: Methods &We then sought to examine the relationship be-
tween enhancer length and expression per vector
genome. Thus, primary human CD34+ HSPCs
were transduced at various MOIs and cultured
under erythroid differentiation conditions for
14 days. Expression by each vector was measured
as percentages of bAS3-globin transcripts to total
b-globin-like transcripts, normalized to VCN,
and plotted by function of enhancer length.
Normalized expression levels were seen to corre-
late strongly with enhancer length (Figure 3E).
Comparing %bAS3-globin transcript levels and
VCN, each vector had a characteristic linear rela-
tionship (Figure 3F). The larger vectors achieved
higher expression per VCN, but the smaller vec-
tors were able to reach a higher VCN and
compensate for lower expression per VCN to
yield total amounts of expression that were
similar. For example, Lenti/bAS3-FB was seen to
provide slightly higher levels of expression thandid the similarly sized 80 vector (as shown by the increased slope of
the fitted line), but this difference failed to reach significance. All
LV-MPRA vectors displayed erythroid-specific expression patterns,
as expression was non-detectable in transduced HSPCs cultured
under myeloid differentiation conditions (Table 1).
We then sought to determine optimal enhancer orientation and
arrangement. Sequences within the 95th percentile of highest expres-
sion were arranged in sense orientation with those associated with
HS1 placed closest to the promoter (95-Sense). Enhancers were also
arranged in an anti-sense orientation, with those elements associated
with HS1 placed farthest from the promoter (95-Antisense). En-
hancers were also arranged in anti-sense orientation with those
associated with HS1 now placed closest to the promoter (95-Alt
Antisense). A schematic outlining enhancer orientation and
arrangement is provided in Figure S4A. While sequences containing
cryptic polyadenylation sites should have been depleted during viral
genome synthesis and thus eliminated from the initial screen, any
cryptic polyadenylation sites present within incorporated enhancerClinical Development Vol. 17 June 2020 1003
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Figure 3. LV-MPRA-Guided Therapeutic Vector Design and Characterization
(A) Percentile cutoff thresholds were established to identify sequences within a given percentile of expression. Those sequences were then concatenated to produce
composite enhancer elements. (B) Composite enhancers were cloned into the plasmid backbone of a therapeutic lentiviral vector (Lenti/bAS3-FB with LCR DNase-hyper-
sensitive sites (HSs) 2, 3, and 4 removed, packaged, and titered head-to-head, and the quantity of infectious particles were plotted as a function of proviral length (bp). Each
point in the plot represents an individual 10-cm plate of virus titered on HT-29 cells. Proviral length is defined as sequence length from the beginning of the 50 long terminal
repeat (LTR) U3 through the end of the 30 LTRU5. n = 3–9 per arm. (C) Human CD34+ hematopoietic stem and progenitor cells (HSPCs) were transduced with constructs at a
multiplicity of infection (MOI) of 10 (1 107 TU/mL) and cultured under myeloid culture conditions to assess infectivity. Vector copy number (VCN) was determined by droplet
digital polymerase chain reaction (ddPCR) 14 days after transduction. Each point in the plot represents an individual transduction, and the VCN of each transduction is plotted
by function of proviral length. n = 4 per arm. (D) Human CD34+ HSPCs were transduced at MOIs of 1, 3.3, 6.6, or 10 and cultured under myeloid culture conditions to assess
(legend continued on next page)
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sense or alt-antisense orientation.
The collections of enhancer configurations were cloned into the
identical b-globin expression vector backbone and packaged and ti-
tered in parallel. No significant differences in titer were observed
(Figure S4B). Human CD34+ HSPCs were transduced with constructs
at 1x107 TU/mL and cultured for 14 days. No differences in infectivity
(Figure S4C), expression (Figure S4D), or normalized expression
levels per VCN were observed, demonstrating that element direction-
ality or element proximity to the promoter did not diminish vector
production, transduction, or expression (Figure S4E).
Lastly, we sought to confirm that sequences within the 95th percentile
of lowest expression were incapable of enhancing expression above
basal levels offered by the minimal promoter. Sequences within the
95th percentile of lowest expression were identified, concatenated,
and cloned into a b-globin expression vector backbone to generate
95-Negative. This new construct was then compared against a
b-globin expression vector containing only a minimal b-globin pro-
moter as the major regulatory element driving expression (Pro.Only)
and the previously defined (above) 95-Sense construct. Human
CD34+ HSPCs were transduced at an MOI of 10 and cultured under
erythroid conditions for 14 days. The previously defined 95-Sense
construct offered significantly higher levels of normalized expression
when compared head-to-head against other constructs. As expected,
no significant differences in normalized expression between 95-Nega-
tive and Pro.Only were observed, demonstrating that sequences
within the 95th percentile of lowest expression were incapable of
enhancing expression while sequence within the 95th percentile of
highest expression could clearly enhance expression (Figure S5D).
Taken together, these data demonstrate that cis-regulatory elements
identified using LV-MPRA fulfill the major tenet that defines en-
hancers, which is the ability to increase transcription from a promoter
independently of direction or juxtaposition.57,58 These data also
demonstrate that LV-MPRA can be used to concatenate regulatory
elements of various lengths that (in this case) offer predictable
patterns of performance across multiple categories (additional data
are provided in Figure S6).
In Vivo Characterization of LV-MPRA-Based Therapeutic
Vectors in the SCD Mouse Model
The best performing LV-MPRA constructs, 95 and 97.5, which were
intermediate for length, titer, and expression, were then compared
to Lenti/bAS3-FB in the “Townes” mouse model of SCD to evaluate
their ability to induce hematologic correction. Lineage-depleted
bone marrow (BM) cells were obtained from homozygous bS/bSvector infectivity. The VCN of each transduction is plotted by function of vector dose. Slo
transduced at MOIs of 1, 3.3, 6.6, or 10 and differentiated under erythroid culture condit
reverse transcription (RT) ddPCR and normalized to VCN. Normalized expression value
HSPCs were transduced at MOIs of 1, 3.3, 6.6, or 10 and differentiated under erythroid c
by function of their corresponding VCNs. n = 12–28 per arm.
Moleculadonor mice and pre-stimulated for 1 day. Cells were transduced at
equal MOIs by the different vectors and after 1 day delivered by
retro-orbital injection into lethally irradiated GFP-transgenic
mouse recipients (B6-GFP; Jackson Laboratory). Three independent
experiments were conducted, and in vitro VCN was determined
from the transduced cell product 14 days after transduction
(Table 2). Peripheral blood (PB) samples, acquired at 4 and 16 weeks
post-transplantation, were assessed for engraftment by flow cytom-
etry for GFP-negative donor cells, gene marking in circulating cells
(VCN by droplet digital PCR [ddPCR]), and blood hemoglobin
(Hb) concentration and composition by high-performance liquid
chromatography (HPLC).
Mice with BM donor engraftment <97% at week 16 were excluded
from analyses, asR4% residual wild-type (WT) recipient RBCs could
mask adverse pathophysiology induced by bS/bS donor cells.59 Week
16 engraftment efficiency in PB or BM (by fluorescence-activated
cell sorting [FACS] or HPLC) were not different among experimental
arms (Figures S7A–S7C). Average gene transfer efficiency seen in
circulating PB (Figure 4A) and BM cells (Figure S7D) differed
significantly among experimental arms, and it demonstrated that
constructs with decreased total enhancer lengths offered superior
transduction efficiency.
Quantification of HbbAS3 tetramers in PB lysates was accomplished
using HPLC. To compare differences in normalized expression be-
tween each experimental arm, the %HbbAS3/total Hb tetramers was
normalized to PB VCN for each mouse and plotted. Constructs
with larger enhancers offered superior expression per vector
genome, with overall trends reflecting those seen in in vitro experi-
ments, where constructs with larger enhancers offered superior
expression per vector genome (Figure 4C).
Surprisingly, average total levels of HbbAS3/total Hb tetramers were
not different among experimental arms, demonstrating that lower
expression levels from smaller vectors were compensated for by
gains in transduction efficiency (Figure 4B). Expression findings
were also confirmed by measuring %bAS3-globin mRNA to
b-globin mRNA in BM obtained 16 weeks post-transplantation
and then normalizing those values to BM VCN (Figures S6E and
S6F).
Finally, hematologic indices were measured using PB obtained at 4
and 16 weeks post transplantation. When compared to mice trans-
planted with mock-transduced BM cells, Hb levels, red blood cell
counts, and hematocrits were significantly higher in mice that
were transplanted with BM transduced with vectors designed using
LV-MPRA.pes represent linear regressions. n = 12–28 per arm. (E) Human CD34+ HSPCs were
ions. Percentages of bAS3-globin RNA to total b-globin-like RNA were determined by
s are plotted as a function of proviral length. n = 12–28 per arm. (F) Human CD34+
ulture conditions. Percentages of bAS3-globin RNA to total b-globin RNA are plotted
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Table 2. In Vitro VCN of Gene-Modified bS/bS Lin– BM Cells before
Transplant
Lenti/bAS3-FB 95 97.5
Transduction condition (TU/mL) 6.6  106 6.6  106 6.6  106
In vitro VCN experiment 1 1.6 ND 7.2
In vitro VCN experiment 2 1.5 2.7 4.9
In vitro VCN experiment 3 1.2 3.0 5.7
TU, transduction units; VCN, vector copy number; ND, not done.
Table 1. Comparison of Normalized Expression between Culture
Conditions
Vector
Erythroid
VCN
Erythroid Expression
(%bAS3/VCN)
Myeloid
VCN
Myeloid Expression
(%bAS3/VCN)
98.75 3.4 (±0.5) 6.8 (±1.3)
3.3
(±1.3)
not detectable
97.5 3.1 (±0.8) 7.9 (±2.7)
2.6
(±0.7)
not detectable
95 2.1 (±0.4) 10.5 (±3.3)
1.9
(±0.7)
not detectable
90 1.1 (±0.1) 16.1 (±0.7) 1.5 (0.7) not detectable
Lenti/
bAS3-FB
1.1 (±0.2) 19.9 (±2.4)
1.0
(±0.3)
not detectable
Molecular Therapy: Methods & Clinical DevelopmentAt week 16, Hb levels of mice that received mock-transduced cells
were 7.9 g/dL on average while the Hb levels of mice that received
BM transduced with Lenti/bAS3-FB, 95, or 97.5 were 11.0, 11.2, and
11.6 g/dL on average, respectively (Figure 4D). RBC counts were
also significantly higher for recipients of Lenti/bAS3-FB-, 95-, or
97.5-transduced BM cells (8.5  106, 9.0  106, and 8.5  106 cells/
mL on average, respectively) compared to recipients of mock-trans-
duced BM cells (6.2 106 cells/mL on average). Similar improvements
were seen for hematocrits, where mice that received mock-transduced
cells had hematocrits of 25.2 on average, while mice that received
Lenti/bAS3-FB-, 95-, or 97.5-transduced BM had hematocrits of
30.9, 32.2, and 30.6 on average, respectively. The in vivo data demon-
strate that when LV-MPRA was deployed to aid therapeutic vector
development, identification of correct combinations of enhancers
capable of providing sufficient levels of transgene expression was
achieved.
DISCUSSION
Control over LV transgene expression is typically achieved by
including cis-regulatory elements that enhance transcription of a
LV’s internal promoter in a cell type-specific pattern.60 While
genome-scale cell line-based genetic and epigenetic studies have
generated an impressive collection of candidate enhancers, these
studies utilize indirect measurements (histone modification,
chromatin accessibility, and bound transcriptional co-activators) to
predict enhancer locations.61 Moreover, the limitations of these
studies fail to provide exact boundaries of sequence-intrinsic en-
hancers (i.e., the actual sequences that provide enhancer activity).
To date, the vast majority of putative cis-regulatory elements have
yet to be characterized in LV systems.
Therapeutic expression vectors are traditionally designed by testing
individual candidate enhancers for their ability to potently drive
cell type-specific transgene expression, in addition to determining
how incorporation influences titer and infectivity. While criteria
can be imposed to reduce the number of candidate enhancer elements
for evaluation, only a handful of elements can be tested at a time,
as current throughput limitations restrict the number of LVs that
can be evaluated in parallel. Confounding the issue of low throughput,1006 Molecular Therapy: Methods & Clinical Development Vol. 17 Junespecific combinations of elements must also be uncovered to achieve
temporal and spatial control over transgene output. Thus, the
challenges in developing expression vectors produced at high titers,
while offering both robust infectivity and appropriate levels of cell
type-specific protein expression, are elevated.
Multiple groups have used high-throughput approaches toward dis-
secting the functional activities of cis-regulatory elements in various
contexts;30–39 however, no group has applied their findings toward
therapeutic vector design. While each group developed an assay
that possessed aspects of an ideal functional assay for therapeutic
vector development, each approach had its own unique advantages
and limitations. The ideal functional assay needed was one that can
unbiasedly screen thousands of DNA sequences derived from large
genomic regions for intrinsic enhancer activity and do so in the
context of a therapeutic vector integrated into a relevant cell type.
To this end, we developed an LV-MPRA to generate a continuous
and quantitative map on which to dissect the ability of putative
cis-regulatory sequences to enhance expression in an erythroid
progenitor cell line. By using DNA oligonucleotide synthesis to
create the starting material required to create thousands of barcoded
LVs with each harboring a known LCR fragment, we were able to
transcend the traditional limitations of therapeutic vector develop-
ment by using barcode sequencing to digitally measure enhancer
activity across thousands of sequences.
While results of our initial pilot study (provided in Supplemental
Information) demonstrated that a construct harboring the minimal
b-globin promoter alone generated detectable levels of basal activity,
the construct harboring an HS2 fragment provided 5-fold higher
levels of activity, suggesting that other sequences possessing compa-
rable intrinsic enhancer activity could be detected. The use of 103-
bp insert size influenced the dynamic range in the assay by decoupling
the influence of flanking DNA on expression offered by core se-
quences, which is consistent with previous findings demonstrating
the weak role of even larger core fragments (200–400 bp) on
enhancing expression when compared to appropriate controls.42
Averaging expression between three barcodes was sufficient
to generate a map of expression activity once statistical boot-
strapping was implemented. The resultant map possessed
peaks that aligned with previously published chromatin2020
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Figure 4. In Vivo Analysis of Peripheral Blood from “Townes” Mouse Model of SCD
Peripheral blood (PB) was obtained at weeks 4 and 16 after transplant. Mice with >97% donor engraftment were analyzed. Mock, n = 7; Lenti/bAS3-FB, n = 5; 95, n = 5; 97.5,
n =5; SCD (Townesmousemodel of SCD), n = 3;WT (B6-GFP), n = 3. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (A) Peripheral blood VCN by ddPCR. (B) Percentages
Hb (hemoglobin) bAS3-globin tetramers in PB lysates measured by high-performance liquid chromatography. (C) Percentages of Hb bAS3-globin tetramers normalized to PB
VCN. (D) Hb (g/dL) levels. (E) Red blood cell (RBC) count (106). (F) Hematocrit (HCT) level (percentages). All error bars represent standard deviation with mean.
www.moleculartherapy.orgimmunoprecipitation sequencing (ChIP-seq) data denoting puta-
tive positions of enhancer elements. Notably, the same HS2
sequence tested in the pilot experiment exhibited the highest
levels of activity, while HS5, a sequence demonstrated in previous
studies to be a potent insulator element,23 was shown to lack
any enhancing activity in our analysis. Moreover, the consistent
level of noise across the map (ranging from 0.3 to 0.5) was
consistent with levels of activity offered by the minimal promoter
alone, as demonstrated in the pilot study.MoleculaWhen the percentile cutoff of 80% was imposed to identify se-
quences within the 80th percentile of highest expression, we
were able to develop a novel regulatory sequence that when
incorporated into a therapeutic expression vector backbone pro-
duced a construct, termed 80, with no significant differences in
titer, infectivity, or expression when compared to Lenti/bAS3-FB.
Given that boundaries defining the enhancer elements of Lenti/
bAS3-FB have been undergoing continuous refinement for the
past 20 years,14 we found it noteworthy that our approach wasr Therapy: Methods & Clinical Development Vol. 17 June 2020 1007
Molecular Therapy: Methods & Clinical Developmentable to create a comparable regulatory sequence of novel compo-
sition in a matter of weeks.
Since the 80 vector was so analogous to Lenti/bAS3-FB (in relationship
to robust expression but diminished titer and gene transfer), we decided
to test the smaller 95 and 97.5 in the Townes mouse model of SCD.
Although95 and 97.5were found to possess 50%and30%of the expres-
sion activity of Lenti/bAS3-FBper vector genome, respectively, these los-
ses in expressionwere overcome by gains in infectivity, resulting in pro-
duction of comparable total amounts of bAS3-mRNA and protein in
circulating murine RBCs, thus reversing the disease phenotype. While
an increase in VCN to compensate for expression is typically undesir-
able, gene transfer is typically less than one copy per cell in the case of
traditional b-globin-expressing LVs. Thus, an increase to a VCNof 2–4
is not excessive, as seen with the 95 vector. More importantly, 95 and
97.5 were found to be produced at significantly higher titers when
compared to Lenti/bAS3-FB, which may hold implications for
improving access to gene therapy by significantly reducing the cost of
vector production through providing higher levels of gene transfer us-
ing the smallest amounts of vector. When combined with transduction
enhancers,62 the use of 95 and 97.5 would lead to even further advan-
tages in drug product quality and cost reduction per patient.
This proof-of-principle study demonstrates that in mere weeks, line-
age-specific therapeutic expression vectors were generated that
rivalled a vector that has undergone years of refinement. Designing
LVs using sequence-intrinsic enhancers of the LCR was done not
just because the locus is such a hot gene therapy target, but also
because fine mapping represents a high bar to clear since the locus
has been studied in such detail for decades. The real power of this
LV-MPRA approach should come into play when far less studied
loci are targeted for gene therapy vector design and coupled with
state-of-the-art machine learning algorithms.63 The approach out-
lined herein facilitates the rapid development of any therapeutic
vector requiring cell type-specific expression while advancing the
prospect of realizing gene therapy’s promise.
As an alternative to gene addition using LVs, a variety of approaches
are being developed for genome editing using CRISPR/Cas9 to treat
SCD. Disruption of the key repressor of fetal globin expression,
BCL11A, or its binding site near the g-globin gene or even site-spe-
cific correction of the A/T transversion underlying SCD are in
early clinical or pre-clinical stages. It will remain to be determined
which gene therapy approaches ultimately provides the best efficacy,
safety, and cost-effectiveness. However, LVs have an established
track record of clinical efficacy and safety and thus continue to be
worthy of efforts for optimization.
MATERIALS AND METHODS
LV-MPRA Oligonucleotide Design and Preparation
Pools of synthetic 170-mer DNA sequences were ordered from
CustomArray (Bothell, WA, USA). Each oligonucleotide was de-
signed according to the following scheme: 50 primer amplification
sequence (ATGTTTTTCTAGGTCTCGAG)/103-bp LCR query1008 Molecular Therapy: Methods & Clinical Development Vol. 17 Junesequence/BmtI site/4-bp spacer/SalI site/barcode/30 primer amplifi-
cation sequence (CTTTGTTCCCTAAGTCCAAC).
Each oligonucleotide possessed a 103-bp query sequences derived
from a larger 16-kb LCR sequence (http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&position=chr11:5296481-5313207 GRCh37/
hg19; Chr11;5,296,481-5,313,207; UCSC Genome Browser), with
each subsequent oligonucleotide possessing a similar query sequence
offset by 4 bp until complete coverage of the larger sequence
was achieved. A total of 4.2  103 unique oligonucleotides were
needed to achieve 1 coverage of the larger 16-kb LCR sequence.
Each query sequence was assigned three unique 13-bp barcodes,
tripling the diversity of sequences to 1.2  104. Antisense versions
of the query sequences were also included, doubling the total number
of unique query/barcode pairs to 2.5  104.
Primer “Custom Array Rev” (Table S1) was used to convert full-
length DNA microarray synthesized oligonucleotides into double-
stranded DNAs (dsDNAs) by primer extension. Twelve reactions us-
ing MyTaqRed (Bioline Meridian Life Science, Memphis, TN, USA)
were established in parallel, with each reaction containing 200 ng
of template and 4 mL of reverse primer. A single cycle of PCR
amplification was performed at an annealing temperature of 45C.
Reaction products were purified using a PureLink PCR purification
kit (Thermo Fisher Scientific,Waltham,MA, USA) to deplete residual
primers and single-stranded DNA (ssDNA) products and pooled.
Primers “CustomArray FWD” and “CustomArray REV” were then
used to amplify 170-bp dsDNA fragments. Twelve PCR reactions
were performed using MyTaqRed (Bioline Meridian Life Science,
Memphis, TN, USA) with 200 ng of dsDNA template and amplified
for six cycles with an annealing temperature of 45C. Reaction
products were purified by column and pooled. The purified reaction
products were then used in LV library construction.
LV-MPRA Library Construction
We created a streamlined version of a b-globin expression vector for
use in LV-MPRA library construction. The modified construct was
made by replacing the reverse-oriented human genomic elements
(full-length LCR HS2 and HS3 enhancer elements, minimal b-globin
gene promoter, bAS3 transgene with introns, exons, and 30UTR) of
Globe1-AS3-FB with a minimal b-globin gene 30 UTR sequence
and an EcoRV site. The plasmid backbone was linearized using
EcoRV enzyme in buffer 3.1 (New England Biolabs, Ipswich, MA,
USA) and 50 DNA ends dephosphorylated using recombinant shrimp
alkaline phosphatase (New England Biolabs, Ipswich, MA, USA). Re-
action products were pooled and run on 1% agarose gel, and DNA of
correct length was gel extracted and purified using a PureLink quick
gel extraction kit (Invitrogen, Carlsbad, CA, USA). Pools of 170-bp
dsDNA fragments were cloned into linearized plasmid backbones
using an NEBuilder HiFi DNA assembly (New England Biolabs,
Ipswich, MA, USA) mix to create the “pre-complete library” (the 50
and 30 primer amplification sequences of the 170-bp dsDNA frag-
ments had homology with the DNA ends of the linearized plasmid2020
www.moleculartherapy.orgbackbones). A total of six 20-mL NEBuilder reactions were estab-
lished, each containing 400 ng of purified plasmid backbone and
50 ng of purified 170-bp dsDNA fragments. Reactions were incubated
at 50C for 60 min. The NEBuilder reactions were pooled, purified
using a 2.5 Agencourt AMPure XP beads kit (Beckman Coulter,
Brea, CA, USA), and eluted into a final volume of 24 mL of DNase-
free water. A total of six transformation reactions were performed
with NEB Stable Competent E. coli (New England Biolabs, Ipswich,
MA, USA) and 4 mL of purified plasmid product. Each transformation
was recovered in 500 mL of SOC medium for 30 min, pooled, and
expanded in 500 mL of Luria-Bertani (LB) medium overnight.
Large-scale plasmid DNA isolation was then performed using a
PureLink HiPure plasmid maxiprep kit (Invitrogen, Carlsbad, CA,
USA) to create a pre-complete library.
The pre-complete library was then linearized with SalI and BmtI en-
zymes in buffer 3.1 (New England Biolabs, Ipswich, MA, USA). A to-
tal of 12 digestion reactions were established with each containing
2 mg of plasmid. Digests were incubated overnight at 37C with re-
combinant shrimp alkaline phosphatase. Reaction products were
pooled and run on 1% agarose gel, and DNA of correct length was
gel extracted and purified.
The bAS3-P2A-mCit expression cassette was liberated from its pCR-
BluntII-TOPO vector backbone using SalI and BmtI restriction en-
zymes in buffer 3.1 (New England Biolabs, Ipswich, MA, USA). A
total of 12 digestion reactions were established, each containing
2 mg of plasmid. Digests were incubated overnight at 37C. Reaction
products were pooled and run on 1% agarose gel, and DNA of correct
length was gel extracted and purified.
The expression cassette was then ligated into the linearized pre-com-
plete library. A total of six ligation reactions were established, with
each containing 200 ng of linearized plasmid and 430 ng of insert.
The ligation reactions were pooled, purified using a 2.5 Agencourt
AMPure XP beads kit (Beckman Coulter, Brea, CA, USA), and eluted
into a final volume of 24 mL. A total of six transformation reactions
were performed with NEB Stable Competent E. coli (New England
Biolabs, Ipswich, MA, USA) and 4 mL of purified plasmid product.
Each transformation was recovered in 500 mL of SOC medium for
30 min, pooled, and expanded in 500 mL of LB medium overnight.
Large-scale plasmid DNA isolation was then performed using a
PureLink HiPure plasmid maxiprep kit (Invitrogen, Carlsbad, CA,
USA) to create a “complete library.”
Vector Production and Titration
Transient transfection of 293T cells using the third-generation LV
packaging system64 provided packaged virus particles. Viral superna-
tants were then directly used for titer determination or concentrated
by tangential flow filtration, as described by Cooper et al.65 Briefly, the
HT-29 human colorectal carcinoma cell line was transduced with
different dilutions of both raw and concentrated vectors. To calculate
titers, cells were harvested and VCNs were determined by ddPCR
approximately 60 h post-transduction.MoleculaHUDEP-2 Cell Culture and Transduction
HUDEP-2 cells (provided by Dr. Y. Nakamura, RIKEN BioResource
Center, Tsukuba, Ibaraki, Japan) were maintained in Iscove’s modi-
fied Dulbecco’s medium (IMDM; Gibco, Grand Island, NY, USA)
supplemented with 1 mM dexamethasone (Sigma-Aldrich, St. Louis,
MO, USA), 1 mg/mL doxycycline (Sigma-Aldrich, St. Louis, MO,
USA), 50 ng/mL human stem cell factor (SCF), 3 U/mL erythropoi-
etin (EPO) (all cytokines were acquired from PeproTech, Rocky
Hill, NJ, USA), and 1 glutamine, penicillin, and streptomycin
(Gemini Bio-Products, Sacramento, CA, USA). A total of 2.5  106
HUDEP-2 cells were transduced with 5 mL of raw virus in a total
volume of 10 mL in a T75 flask. Approximately 24 h later, cells
were pelleted, medium was changed, and cells were expanded for
7 days. Approximately 1.0  107 transduced HUDEP-2 cells were
then harvested for gDNA isolation, and the remaining cells were
plated on an MS5 stromal cell layer in IMDM supplemented
with 1 glutamine, penicillin, and streptomycin, holo-human trans-
ferrin (330 mg/mL, Sigma-Aldrich, St. Louis, MO, USA), heparin
(2 IU/mL, Sigma-Aldrich, St. Louis, MO, USA), recombinant human
insulin (10 mg/mL, Sigma-Aldrich, St. Louis, MO, USA), 3 U/mL
EPO, and 5% inactivated human plasma (Grifols USA, Los
Angeles, CA, USA). Cells were co-cultured for 4 days, after which
1.0  107 cells were harvested for RNA extraction.
Barcode Generation
gDNA was extracted from HUDEP-2 cells 8 days after transduction
using a PureLink gDNAmini kit (Thermo Fisher Scientific, Carlsbad,
CA, USA). Total RNA was extracted from HUDEP-2 cells 4 days
after the start of differentiation using the RNesay mini kit (QIAGEN,
Valencia, CA, USA). Total RNA was separated into eight 10-mL ali-
quots for storage. Reverse transcription of total RNA was carried
out in parallel across six reactions each using 10 mL of total RNA,
1 mL of first-strand primer, 2 mL of 0.1 mM DTT, 4 mL of first-strand
synthesis buffer, 1 mL of 10 mM 20-deoxynucleoside 50-triphosphate
(dNTP), 1 mL of RNaseOUT, and 1 mL of 200 U/mL Moloney murine
leukemia virus (M-MLV) reverse transcriptase (all from Invitrogen,
Carlsbad, CA, USA). The first-stand primer was designed to enrich
for only cDNAs that contained barcodes and thus possessed homol-
ogy to mCit to allow for creation of cDNAs comprised of a sequence
spanning mCit and the 30 UTR of the barcoded bAS3-P2A-mCit
mRNAs. To amplify barcodes from both gDNA, RNA, and complete
library plasmid, first-strand primer (nested) and second-strand
primer were used, as they flank the barcoded region. Following
PCR amplification, both the gDNA and cDNA barcodes were purified
and submitted to the University of California Los Angeles (UCLA)
Technology Center for Genomics & Bioinformatics Sequencing
Core, Department of Pathology and Laboratory Medicine, for library
construction and PEx150 Illumina sequencing. The KAPA LTP li-
brary preparation kit (catalog no. KK8232, Roche) was used for li-
brary preparations, and libraries were sequenced using a single lane
of the Illumina HiSeq 3000. Reads that perfectly matched the first
14 nt of the amplicon were included in subsequent analysis. We
generated 124 million reads from the complete library plasmid, 49
million reads from the gDNA, and 117 million reads from ther Therapy: Methods & Clinical Development Vol. 17 June 2020 1009
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reads (r = 0.854), allowing the plasmid barcode reads to be used for
normalization.
Barcode Quantification and Sequencing
The constant sequences before (50-ACTTAGGGAACAAAG-30) and
after (50-GTCGACATGCTAGC-30) the barcode were used to locate
barcodes from sequencing data, and the frequencies of barcodes
were determined in plasmid, gDNA, and cDNA. To quantify the
enhancing ability of each LCR fragment, the read counts were first
normalized by sequencing depth, and cDNA barcode counts were
divided by plasmid barcode counts after the sums of matched barcode
triplets were calculated (each LCR fragment was associated three
unique barcodes). The log(x + 1) values were calculated and used to
represent enhancing ability.
The LCR sequences tested were 103 bp in length, with each neigh-
boring sequence beginning 4 bp away from the next. Thus, a single
nucleotide should be covered by 50 different sliding fragments. Statis-
tical bootstrapping was used to calculate the mean of the non-zero
counts in the 50 covering fragments to represent the enhancing
score. The bootstrap is a widely applicable and extremely powerful
statistical tool that is applied in machine learning models to make
predictions on data not included in training data. Bootstrapping
allowed for determination of an enhancing score for a given query
sequence by resampling the neighboring 50 values 100,000 times
and then replacing that value with the estimated value in an iterative
fashion. This process allows for reduction of noise, as a cluster of
neighboring sequences should offer similar averaged levels of expres-
sion activity given the narrow sequence length being assayed. The
enhancing score was then used to make the map of enhancer activity
across the LCR in Figure 2A.
To quantify putative TFBSs present within the LCR in the enhancer,
FIMO 5.0.153 was used to infer locations of TFBSs across the query
sequence. A total of 771 motifs for human transcription factors
from HOCOMOCOv11 were input to FIMO for searching, and the
p value threshold was set to 0.0001. The number of motifs binding
to each nucleotide was calculated and plotted in Figure 2C.
BM CD34+ Cell Culture and Transduction
All BM aspirates were obtained from voluntary healthy donors
supplied by AllCells (Alameda, CA, USA). BM mononuclear cells
were isolated by Ficoll-Hypaque density gradient centrifugation.
CD34+ HSPCs were enriched using a CD34+ MicroBead kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). Enriched CD34+ HSPCs
were cryopreserved in fetal bovine serum supplemented with 10%
dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) in liquid
nitrogen. Cells were thawed and plated on non-tissue culture-
treated six-well plates pre-coated with RectroNectin (20 mg/mL,
Takara Shuzo, Otsu, Japan) at 1  106 cells/mL. Cells were pre-stim-
ulated for 16–24 hours in X-VIVO 15 medium (Lonza, Basel,
Switzerland) supplemented with 1 glutamine, penicillin, and
streptomycin (Gemini Bio-Products, Sacramento, CA, USA), human1010 Molecular Therapy: Methods & Clinical Development Vol. 17 JuneSCF (50 ng/mL), human Flt-3 ligand (50 ng/mL), human thrombo-
poietin (50 ng/mL), and human interleukin-3 (20 ng/mL; all cyto-
kines were acquired from PeproTech, Rocky Hill, NJ, USA). Concen-
trated viral supernatants were used at various MOIs to transduce
CD34+ HSPCs for 24 h. These cells were washed, re-plated, and
cultured under myeloid or erythroid culture conditions, as described
by Romero et al.66 On day 14 of culture, gDNA and/or mRNA was
extracted from transduced cells.
ddPCR for VCN and %bAS3 mRNA Quantification
gDNA was extracted using a PureLink gDNA mini kit (Invitrogen,
Carlsbad, CA, USA). VCN was calculated by using probes SCD4
(human Syndecan 4) as a reference and HIV-1 Psi as a target. ddPCR
was carried out as described in Urbinati et al.67 An RNeasy Plus
mini kit (QIAGEN, Valencia, CA, USA) was used for RNA extraction
followed by reverse transcription as described by Urbinati et al.67
Probes HBBTotal as a reference and HbbAS3 as a target were used to
generate droplets for ddPCR, as described by Hindson et al.68 Drop-
lets were analyzed for absolute quantification of the bAS3 gene
expression normalized to the total b-globin gene expression.
In Vivo Experiment in SCD Mouse Model
BM from 8- to 12-week-old homozygous bS/bS Townes mice (Jack-
son Laboratory stock #013071) were lineage-depleted using the line-
age cell depletion kit from Miltenyi Biotec. Lineage-negative (Lin)
cells were pre-stimulated for 24 h in StemSpan (STEMCELL Technol-
ogies, Vancouver, BC, Canada) supplemented with murine SCF
(100 ng/mL), human interleukin 11 (100 ng/ mL), murine interleukin
3 (20 ng/mL), and human FLT-3 ligand (100 ng/mL). Pre-stimulated
Lin cells were plated at 2 106 cells/mL in a total volume of 2 mL in
non-tissue culture-treated six-well plates that were pre-coated with
recombinant retronectin. Cells were then transduced at 1  107
TU/mL, with volumes used of each vector adjusted based on the titers
of the vector preparations. Thus, the MOI was 5 TU/cell for all vec-
tors, based on vector titers determined with HT29 cells.65 Twenty-
four hours later, 1–2 million transduced cells were delivered
by retro-orbital injection after recipient mice (B6-GFP transgenic;
Jackson Laboratory) were lethally irradiated (1,075 cGy, split in
two fractions).
PB samples were collected at weeks 4 and 16 to measure VCN of
engrafted cells by ddPCR, expression of HbbAS3 Hb by HPLC, and
to determine red blood cell (RBC) indices. At week 16, mice were
euthanized and BM cells were used to measure engraftment by
flow cytometry (GFP+/), VCN, and expression.
HPLC
To characterize and quantify Hb tetramers, including human
HbS and HbbAS3, and murine HbA and HbF, 1 mL of murine
PB was lysed in 25 mL of hemolysate and incubated at room tem-
perature. Hemolysates were then centrifuged at 500  g for 10 min
at 4C to remove RBC ghosts. The lysates were then stored
frozen at 80C and later thawed and processed as described by
Urbinati et al.672020
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All data are reported as mean ± standard deviation of the mean unless
otherwise stated. Statistical analyses were performed using GraphPad
Prism version 7.0 (GraphPad, San Diego, CA, USA). The statistical
significance between two averages was established using unpaired t
tests. When the statistical significance between three or more averages
was evaluated, a one-way ANOVA was applied, followed by multiple
paired comparisons for normally distributed data (Tukey’s test).
When the normality assumption was violated, a Mann-Whitney
U test was performed for group-wise comparison instead. Linear
regression analyses were used to determine the correlation between
VCN and bAS3-globin RNA transcript quantities. All statistical tests
were two-tailed, and a p value of < 0.05 was deemed significant.
Human and Animal Subject Oversight
The use of anonymous, commercially-purchased human CD34+ cells
is considered to not be human subjects research and is exempt from
IRB review. The Townes sickle cell disease model mice were used un-
der UCLA Animal Care Committee protocol ARC# 2014-025.
Data Availability
The data and code that support the findings of this study are available
from the corresponding author upon reasonable request.
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